GlassScriptPhysician profile
Philip Lieu
NPI 1164740718
$8,778.43
in general payments reported to CMS, 2019-2025
25 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.75 · 2021: $2,253 · 2022: $846 · 2023: $588 · 2024: $3,810 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,315 · Food and Beverage: $2,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,315.00 |
| Food and Beverage | $2,314.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,526.52 | 2022-2025 | Vabysmo, Susvimo |
| Allergan, INC. | $2,061.35 | 2020-2021 | |
| Beaver-Visitec International, INC. | $1,200.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $326.41 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Abbvie INC. | $323.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $276.35 | 2023-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $274.14 | 2022 | |
| Mallinckrodt Hospital Products INC. | $230.76 | 2020-2025 | Acthar |
| Astellas Pharma US INC | $230.06 | 2024-2025 | Izervay |
| Glaukos Corporation | $189.02 | 2025 | Istent Infinite, Idosetr |
| Bausch & Lomb Americas INC. | $174.11 | 2022-2023 | Xipere |
| Dutch Ophthalmic, USA | $161.41 | 2022 | |
| Amgen INC. | $146.36 | 2025 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $124.72 | 2023 | Lokelma |
| Coherus Oncology, INC. | $97.67 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $95.22 | 2022-2024 | Syfovre |
| Sandoz INC. | $78.57 | 2024 | Cimerli |
| Alimera Sciences, INC. | $72.38 | 2021-2023 | Iluvien |
| Novartis Pharmaceuticals Corporation | $52.75 | 2021 | |
| Biotissue Holdings INC. | $36.47 | 2025 | |
| Harrow Eye, LLC | $28.52 | 2024 | Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.98 | 2021 | |
| Heidelberg Engineering, INC. | $21.60 | 2023 | Spectralis |
| Optos, INC. | $15.32 | 2021 | |
| Alcon Vision LLC | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.